Trial Profile
Continuous Erythropoietin Receptor Activator: Efficacy and Safety of Monthly Administration in Anemia of Chronic Kidney Disease Patients not on Dialysis and not Receiving Esa Treatment
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 03 Mar 2016
Price :
$35
*
At a glance
- Drugs Methoxy polyethylene glycol-epoetin beta (Primary)
- Indications Anaemia; Renal failure
- Focus Adverse reactions; Therapeutic Use
- 03 Mar 2016 New trial record